AKT1 and neoplasm: Therefore, the combination of capivasertib and fulvestrant reduces tumour growth in tumours that are CDK4/6 inhibitor resistant or have been exposed to CDK4/6 inhibitor long term and has efficacy in tumours without mutations in the PI3K-AKT pathway.